In the United States alone, over 550,000 people will die from cancer this year, exceeding the number of U.S. combat deaths for the entire 20th century.

“In my 30 years of cancer research, until Piedmont’s current studies with Taxolog agents, I have never encountered a series of compounds that demonstrate such outstanding antitumor activity against difficult-to-reach solid tumors in nude mice with a single administration of each agent. This series of compounds has excellent potential to contribute one or more promising new anticancer drug candidates.”

--Dr. Daniel Dexter, Senior Research Advisor, Piedmont Research Center

Taxolog, Inc., is a family of people working together to make a difference in the treatment of cancer and other diseases.

This website is your link to an organization committed to producing solutions. Examine this site and uncover Taxolog’s story, gain insight into current research ventures and accomplishments, learn about the people behind the discoveries and more. Be sure to bookmark this page for future reference.

 
  • Signed collaboration agreement with Wyeth Pharmaceuticals, Inc. - June 2001
  • Raised $30 million in private placement - July 2001
  • Initiated Phase-I clinical trials with Milataxel (MAC-321, TL-139) IV - August 2001
  • Ground breaking of Taxolog, Inc., Tallahassee facility - October 2001
  • Initiated Phase-I clinical trials with Milataxel Oral - September 2002
  • Initiated Phase-II clinical trials for Milataxel IV - January 2003
  • Opening of Taxolog, Inc., Tallahassee facility - March 2003
  • Initiated Phase-I clinical trials with Simotaxel IV - April 2004
  • Submitted a CTA for TL-310 Oral - May 2005
  • Completed Phase I Study –TL-310 (2nd QTR 2008)
  • Initiated a phase II Study with Milataxel in Eastern Europe (1st QTR 2008).
  • Obtained Simotaxel from Wyeth and enrolled first patient in a phase one study in September 2008
©2004 Taxolog, Inc.